AMV

AMV Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation immunotherapies for cancer. The company's lead asset, AMV564, is a bivalent bispecific T-cell engager (BiTE) designed to target CD33 and CD3, effectively recruiting T cells to destroy myeloid-derived suppressor cells (MDSCs) and leukemic blasts. This approach aims to relieve immune suppression within the tumor microenvironment and enhance the body's natural anti-tumor response. AMV Therapeutics is currently advancing clinical programs in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and solid tumors. The company's technology focuses on restoring immune surveillance to provide durable clinical benefits for patients with difficult-to-treat malignancies.